Don't worry... major stockpilers realise the potential of Inavir and the BARDA funding backs this up. Coverage in journals helps, but ultimately it will be a proven success if stockpilers start buying. They are the ones which will be acting on the "real" benefits rather than marketing hype.
The Aussie market just doesn't understand how to value biotechs... not a bad thing really, as it allows entry at perhaps "undervalued" prices. Personally I'd like to see a NASDAQ listing before Phase II HRV results are released. Doesn't leave all that much time... they have 6 months to get it up!
BTA price < $1 = a joke Fact that I don't have more cash to invest = a bigger joke
:)
BTA Price at posting:
99.5¢ Sentiment: Buy Disclosure: Held
